Research Grade Solanezumab
Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the Aβ peptide. It recognizes soluble monomeric, not fibrillar, Aβ. Solanezumab (formerly known as LY2062430) is a monoclonal antibody being developed by Lilly as a potential therapy for people with mild cognitive impairment caused by Alzheimer’s disease.
Product Specifications
Product Name Alternative
LY2062430, CAS: 955085-14-0
Accession Number
P05067
Expression System
Mammalian Cells
Reactivity
Human
Applications
Research Grade Biosimilar
Stability
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks) . Store at -20°C 12 months. Store at -80°C long term.
Endotoxin
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Form
Liquid
Buffer
0.01M PBS, pH 7.4.
Notes
For research use only. Not suitable for clinical or therapeutic use.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
